Tag Archives: Seagen

Affected by reduced demand for Covid drug Molnupiravir, Merck has published reduced revenue figures according to its Q1 2023 report. Multinational pharmaceutical giant Merck & Co Inc (NYSE: MRK) has released its Q1 2023 report. The company’s figures show a reduction in revenue due to several factors, including a plunge in sales. According to published figures, Merck’s Q1 revenue is 9% lower than reported in Q1 2022. This is mainly because its Molnupiravir Covid treatment drug has seen...

Checking if the site connection is secure Enable JavaScript and cookies to continue www.coinspeaker.com needs to review the security of your connection before proceeding.